Wcn26-506 Symptomatic Recurrent Bilateral Pleural Effusions Requiring Repeated Therapeutic Thoracentesis in Esrd on Maintenance Hemodialysis: Is This Pulmonary Hypertesnion, Hypervolemia or Is It Dasatinib-Associated Adverse Reaction?

Dasatinib, a second-generation tyrosine kinase inhibitor (TKI), has proven to be effective for the long-term treatment of chronic myeloid leukemia (CML), both as initial and subsequent lines of therapy. Pleural effusion is an adverse event that has been reported more commonly with Dasatinib than with other TKIs in patients with leukemia. Dasatinib use can result in pleural effusion in some patients, occurring at any time during treatment and commonly characterized as mild to moderate in severity.